IMDX (Insight Molecular Diagnostics) Market Value to Book Value Ratio

Insight Molecular (IMDX) - corporate logo

Insight Molecular Diagnostics is building a staff of bioinformaticians and laboratory technicians whose work strictly complies with FDA standards. The business relies on high-tech biomarker research for personalized medicine. This chart shows the market price on the GURU.Markets platform is -4.63. However, the company faces high R&D expenditures and uncertainty regarding the receipt of insurance reimbursements.

IMDX - imdxinc.com Market-to-Book Ratio over the range 06/19/2025 - 10/27/2026
Flagship merchandise of imdxinc.com

Insight Molecular Diagnostics (IMDX) creates high added value through unique intellectual assets by developing early cancer diagnostic systems. This metric is calculated as the ratio of the market value of all shares to the company's net equity. It demonstrates the premium the market is willing to pay for future business growth beyond the value of its tangible resources. The upward trend confirms the capitalization of its technological advantage. By analyzing the P/BV ratio of Insight Molecular Diagnostics (IMDX), an investor determines the degree of asset overvaluation.

Direct competitors

Market Cap to Net Assets Ratio Agilent Technologies|DGX (questdiagnostics.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio ILMN|Market Cap to Net Assets Ratio Exact Sciences Corp|PerkinElmer - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Bio-Rad Corp (BIO)|NNNN - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio soterahealth.com SHC|QuidelOrtho Corporation - Market Capitalization to Book Value Ratio|OPK: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio CareDx|Maravai (MRVI) - Capitalization to Book Value Ratio|FLGT (Fulgent Genetics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio LAB|Market Value to Book Value Ratio Cytek Biosciences (CTKB)|Market Value to Book Value Ratio OraSure Technologies, Inc. OSUR|XGN: Market Cap to Net Assets Ratio|MDxHealth, Inc. - Market-to-Book Ratio|Market Value to Book Value Ratio LUCD (Lucid Diagnostics Inc.)|PRE - Market Capitalization to Book Value|trinitybiotech.com - Market Capitalization to Book Value Ratio|PRPH (ProPhase Labs Inc) - Market Capitalization to Book Value|AIMD: Market Value to Book Value Ratio|Market Capitalization to Book Value CoDx|HSCS (Heart Test Laboratories) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value BMRA (biomerica.com)|CDIO - Market Value to Book Value Ratio|Virax Biolabs Group Limited - Capitalization to Book Value Ratio|Market Value to Book Value Ratio BJDX (Bluejay)|AWH - Market Capitalization to Book Value|Accelerate Diagnostics - Market Capitalization to Book Value Ratio|CENTOGENE (CNTG) - Market Capitalization to Book Value|Enzo Biochem Inc. - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Fresh2|Genetic Technologies (GENE) - Market Capitalization to Book Value Ratio|Market Value to Book Value 23andMe Inc ME|Market Cap to Net Assets Ratio Psychemedics (PMD)